Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Pegfilgrastim Biosimilars Market Set To Climb From $2.04 Billion In 2026 To $2.65 Billion By 2030
The pegfilgrastim biosimilars market size has experienced significant expansion in recent years. It is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.3%. This historical growth can be linked to the high cost of originator pegfilgrastim, the limited availability of biosimilars, an expanding cancer patient population, a rise in chemotherapy procedures, and enhanced awareness of neutropenia management.
The pegfilgrastim biosimilars market size is anticipated to demonstrate robust expansion in the coming years. It is projected to grow to $2.65 billion in 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This increase during the forecast period can be attributed to the launch of new biosimilars, increasing adoption in supportive oncology care, expansion of hospital and retail pharmacy networks, government incentives for biosimilar usage, and rising investments in stem cell transplantation therapies. Major trends expected over the forecast period include the increasing use of pegfilgrastim biosimilars in supportive cancer care, the broadening of hospital and retail pharmacy distribution channels, a greater emphasis on reducing chemotherapy-induced neutropenia, growth in hematopoietic and peripheral blood stem cell transplantation applications, and rising investments in the treatment of chronic and severe congenital neutropenia.
Get A Free Sample Report With In-Depth Market Insights:
Pegfilgrastim Biosimilars Market Development Factors: What’s Supporting Demand?
Governmental efforts to advance biosimilar development are anticipated to propel the pegfilgrastim biosimilars market. Authorities globally are prioritizing biosimilar development, primarily due to their cost-effectiveness. In the United States, the Food and Drug Administration (FDA) initiated a Biosimilar Action Plan aimed at broadening treatment options. Concurrently, the Australian government reinforced its commitment to the Biosimilar Awareness Initiative, supporting the Generic and Biosimilar Medicines Association with a $5 million grant to bolster general biosimilar education and promote their appropriate dispensing, prescription, and use. These collective government initiatives, by fostering increased production and awareness of biosimilars, consequently contribute to the expansion of the pegfilgrastim biosimilars market.
Pegfilgrastim Biosimilars Market Segmentation: How Does The Market Break Down By Category?
The pegfilgrastim biosimilars market covered in this report is segmented –
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes
Subsegments:
1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia
2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia
Pegfilgrastim Biosimilars Market Transformation Trends: What Innovations Are Driving Change?
Leading companies in the pegfilgrastim biosimilars market are concentrating on technological breakthroughs in biopharmaceuticals, particularly in high-quality biosimilars, to offer safe, effective, and readily available alternatives to original biologic treatments for cancer patients. High-quality biosimilars are defined as biologic medications that closely match the reference product in terms of structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare enterprise specializing in pharmaceuticals and medical technologies, introduced Stimufend, its inaugural pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is provided as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with an integrated needle guard. Through the combination of advanced biosimilar development and user-friendly delivery, Stimufend signifies a technological leap forward in making superior biologic therapies more widely accessible.
Pegfilgrastim Biosimilars Market Competitive Overview And Top Companies
Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm
View The Full Pegfilgrastim Biosimilars Market Report:
Pegfilgrastim Biosimilars Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model